0.593

1.33% -0.008

After Hours: .60 0.007 +1.18%

Barinthus Biotherapeutics Plc Adr (BRNS)

Overview News Price History Financials Discussions Forecast

Barinthus Biotherapeutics Plc Adr stock is traded at $0.593, with a volume of 11,367. It is down -1.33% in the last 24 hours and down -5.72% over the past month. Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Previous Close:

$0.601

Open:

$0.59

24h Volume:

11,367

Relative Volume:

0.27

Market Cap:

$24.22M

Revenue:

$15.12M

Net Income/Loss:

$-66.69M

P/E Ratio:

-0.36

EPS:

-1.647

Net Cash Flow:

$-48.13M

1W Performance:

+0.64%

1M Performance:

-5.72%

6M Performance:

-56.72%

1Y Performance:

-12.92%

1-Day Range:

$0.59

$0.64

1-Week Range:

$0.55

$0.64

52-Week Range:

$0.512

$2.92

Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile

Name

Barinthus Biotherapeutics Plc Adr

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

44 (0) 1865 818808

Address

20400 CENTURY BLVD, GERMANTOWN

Employee

Twitter

Next Earnings Date

2026-03-19

Latest SEC Filings

BRNS's Discussions on Twitter

Compare BRNS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BRNS Barinthus Biotherapeutics Plc Adr	0.593	24.55M	15.12M	-66.69M	-48.13M	-1.647
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Barinthus Biotherapeutics Plc Adr Stock (BRNS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-25-21	Initiated	Jefferies	Buy
May-25-21	Initiated	Morgan Stanley	Overweight
May-25-21	Initiated	William Blair	Outperform
May-24-21	Initiated	H.C. Wainwright	Buy

Barinthus Biotherapeutics Plc Adr Stock (BRNS) Latest News

Mar 28, 2026

ProShares Russell 2000 Dividend Growers ETF $SMDV Shares Sold by Capital Investment Advisors LLC - Defense World

Mar 28, 2026

Mar 16, 2026

Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders? - Finviz

Mar 16, 2026

Mar 14, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm

Mar 14, 2026

Jan 15, 2026

Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Grows By 72.8% - Defense World

Jan 15, 2026

BioHarvest Sciences Inc. (NASDAQ:BHST) Sees Large Increase in Short Interest - Defense World

Jan 15, 2026

Jan 03, 2026

Lowe’s Companies, Inc. $LOW Shares Acquired by Arbor Investment Advisors LLC - Defense World

Jan 03, 2026

Dec 22, 2025

Barinthus Biotherapeutics PLC sponsored ADR (BRNS) upgraded to buy: What does it mean for the stock? - MSN

Dec 22, 2025

Dec 15, 2025

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Dec 15, 2025

Should I buy Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) - zacks.com

Dec 15, 2025

Dec 10, 2025

Barinthus Bio reports positive initial data from celiac therapy trial - Investing.com India

Dec 10, 2025

Nov 20, 2025

Halper Sadeh LLC Encourages HFWA, BRNS, FITB Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.

Nov 20, 2025

HC Wainwright Has Optimistic View of BRNS FY2025 Earnings - Defense World

Nov 20, 2025

Nov 19, 2025

Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights - Finviz

Nov 19, 2025

Nov 12, 2025

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights - Barchart.com

Nov 12, 2025

Nov 11, 2025